REGISTER
Innovent Takes Over Lilly’s Abemaciclib in China; AstraZeneca Signs 2 Deals
China’s biopharma dealmaking stayed strong last week. AstraZeneca signed two China deals in one day, with CSPC on siRNA kidney disease drugs and with Abbisko on an oral PD-L1 small molecule plus osimertinib for lung cancer. Insilico Medicine partnered with Takeda in AI drug discovery, lifting its 2026 disclosed deal value to nearly $7 billion. Lilly also handed mainland China commercialization of abemaciclib to Innovent Biologics.

What happened in the biopharma industry over the past week?

AstraZeneca and CSPC Pharmaceutical Group teamed up again to develop new kidney disease therapies using an siRNA platform. On the same day, AstraZeneca also partnered with Abbisko Therapeutics to advance an oral small-molecule PD-L1 inhibitor in combination with osimertinib for lung cancer. Insilico Medicine entered into an AI drug discovery collaboration with Takeda, bringing its total disclosed deal value for the year to nearly $7 billion. Innovent Biologics took on mainland China commercialization of Lilly’s CDK4/6 inhibitor abemaciclib. Junshi Biosciences granted Greater China rights to its IL-17A monoclonal antibody to a Fosun Pharma subsidiary. Excalipoint also entered a clinical collaboration with Roche on a trispecific T-cell engager combination therapy.

CSPC Teams Up Again with AstraZeneca to Develop New Kidney Disease Drugs via siRNA Platform

On July 2, CSPC Pharmaceutical Group announced that it had entered into a collaboration, option and license agreement with AstraZeneca to jointly develop novel oligonucleotide candidates using its proprietary siRNA drug discovery platform and extrahepatic targeted delivery platform. The deal includes a $30 million upfront payment and a total potential value of $1.77 billion.

Under the agreement, the two companies will jointly discover and develop preclinical candidates (PCCs) against two targets for multiple kidney disease indications. For each PCC program, AstraZeneca may elect to obtain exclusive development, manufacturing and commercialization rights either worldwide or outside China, while CSPC will retain rights in mainland China to one of the PCCs.

This marks the fourth collaboration between CSPC and AstraZeneca since 2024. The two companies have previously partnered in areas including Lp(a) small-molecule inhibitors, AI-driven oral small molecules and long-acting peptides. Among these deals, their peptide weight-loss collaboration signed in January this year carried a total potential value of up to $18.5 billion, setting a record at the time for an innovative drug licensing deal originating in China. The trend underscores how multinational drugmakers are shifting from betting on single assets to forging strategic ties around underlying technology platforms.

AstraZeneca Partners Again with Abbisko to Advance Oral PD-L1 Small Molecule Plus Osimertinib

On July 2, Abbisko Therapeutics announced that it had signed a strategic collaboration agreement with AstraZeneca to jointly advance a Phase I/II clinical study evaluating Abbisko’s proprietary oral small-molecule PD-L1 inhibitor ABSK043 (lumipodlin) in combination with AstraZeneca’s osimertinib, a third-generation EGFR-TKI, in patients with EGFR-mutant, PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

ABSK043 is a potential first-in-class, highly selective oral small-molecule PD-L1 inhibitor that specifically binds to PD-L1 and induces its internalization from the cell surface. In multiple preclinical models, it has demonstrated antitumor activity comparable to that of approved PD-L1 antibodies.

To date, multiple PD-1/PD-L1 antibodies have been approved globally, but no small-molecule agent in this class has yet reached the market. Immunotherapy has shown limited efficacy in EGFR-mutant NSCLC, and combining PD-(L)1 antibodies with EGFR-TKIs has often been associated with significant toxicity. An oral small-molecule PD-L1 inhibitor combined with an EGFR-TKI could therefore offer a new therapeutic option. Abbisko had previously also partnered with Allist Pharmaceuticals to explore ABSK043 in combination with furmonertinib, another third-generation EGFR-TKI, in EGFR-mutant NSCLC.

Insilico Medicine Teams Up with Takeda as Annual AI Drug Discovery Deal Value Nears $7 Billion

On July 2, Insilico Medicine announced a global strategic collaboration with Takeda with a total deal value of up to approximately $600 million. The companies will leverage Insilico’s proprietary end-to-end Pharma.AI platform to jointly advance drug discovery programs across multiple therapeutic areas selected by Takeda.

Insilico will lead the AI-driven drug discovery work and will be responsible for designing and screening candidate molecules, while Takeda will use its global development capabilities to advance clinical validation and will obtain exclusive worldwide development, manufacturing and commercialization rights to the resulting novel therapies. Insilico will receive approximately $60 million in upfront and near-term milestone payments and will be eligible for additional milestone payments as well as tiered royalties on future sales.

This is the fourth major collaboration disclosed by Insilico Medicine in 2026. Following partnerships with Servier in January, Eli Lilly in March and SK Biopharmaceuticals in June, the company’s total disclosed deal value for the year has approached $7 billion. For Takeda, the deal is another step in accelerating its shift toward an AI-native drug discovery model following its earlier collaboration with Iambic in February.

Innovent Takes On Mainland China Commercialization of Lilly’s Abemaciclib

On June 30, Innovent Biologics and Eli Lilly jointly announced a collaboration covering Lilly’s CDK4/6 inhibitor abemaciclib in mainland China. Innovent will be responsible for the importation, sales, promotion and distribution of abemaciclib in mainland China, while Lilly will continue to oversee manufacturing, supply and ongoing development of the product. Abemaciclib has already been approved in China for multiple indications, including early breast cancer and locally advanced or metastatic breast cancer.

The deal also marks a new milestone in the companies’ decade-long partnership. For Innovent, its efficient and broad-reaching commercialization platform is increasingly becoming a monetizable asset in its own right. For Lilly, leveraging a local partner’s commercial infrastructure could help unlock additional value from an established product. This model, under which a multinational drugmaker retains manufacturing while a domestic biopharma company leads market execution, is reshaping how global pharmaceutical companies commercialize products in China.

Junshi Licenses IL-17A Antibody Rights in Greater China to Fosun Wansbang

On July 1, Junshi Biosciences announced that it had signed a licensing agreement with Fosun Wansbang, a subsidiary of Fosun Pharma, granting it development, registration, manufacturing and commercialization rights in Greater China to its proprietary IL-17A monoclonal antibody, ruoqikimab (JS005). Junshi will receive an upfront payment of RMB215 million, and the total potential deal value may reach RMB1.34 billion.

Ruoqikimab is an IL-17A monoclonal antibody developed in-house by Junshi. In a Phase III study in patients with moderate-to-severe plaque psoriasis, the PASI 90 response rate at Week 16 reached 91% in the 150 mg group, while the PASI 100 response rate at Week 52 reached 65%, suggesting best-in-class potential. Its NDA for psoriasis was accepted by China’s National Medical Products Administration in December 2025.

Excalipoint Teams with Roche to Explore Trispecific TCE in DLL3-Positive Solid Tumors

On June 29, Excalipoint announced a clinical collaboration with Roche to explore the combination of its lead investigational candidate EXP011, a DLL3/CD3/4-1BB-targeting T-cell engager, with Roche’s atezolizumab, a PD-L1 inhibitor, in DLL3-positive solid tumors including small cell lung cancer and neuroendocrine tumors.

DLL3 is a highly active target in small cell lung cancer and neuroendocrine tumors, and tarlatamab, a DLL3/CD3-targeting T-cell engager, has already been approved for small cell lung cancer. EXP011 is differentiated by its incorporation of a 4-1BB costimulatory signal alongside T-cell engagement, which may help generate stronger and more durable antitumor responses.

EXP011 is derived from Excalipoint’s EXCOPIA platform, formerly known as TOPAbody. The candidate entered Phase I/II clinical development in October 2025, and its IND application was cleared by the U.S. FDA in January 2026.

0
0
Loading